Akari Therapeutics PLC(AKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AKTX Akari Therapeutics PLC

Market Closed 12-12 16:00:00 EST

0.3894

-0.0206

-5.02%

盘后0.3877

-0.0017-0.44%

18:32 EST

High0.4700	Low0.3661	Vol500.84K
Open0.4009	D1 Closing0.4100	Amplitude25.34%
Mkt Cap13.92M	Tradable Cap2.19M	Total Shares35.74M
T/O216.57K	T/O Rate8.91%	Tradable Shares5.62M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AKTX","market":"US","secType":"STK","nameCN":"Akari Therapeutics PLC","latestPrice":0.3894,"timestamp":1765573200000,"preClose":0.41,"halted":0,"volume":500839,"hourTrading":{"tag":"盘后","latestPrice":0.3877,"preClose":0.3894,"latestTime":"18:32 EST","volume":11964,"amount":4584.065,"timestamp":1765582367185},"delay":0,"floatShares":5620806,"shares":35739730,"eps":-0.569071,"marketStatus":"Market Closed","change":-0.0206,"latestTime":"12-12 16:00:00 EST","open":0.4009,"high":0.47,"low":0.3661,"amount":216573.10088339998,"amplitude":0.253415,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.569071,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":1,"adrRate":2000,"exchange":"NASDAQ","adjPreClose":0.41,"preHourTrading":{"tag":"盘前","latestPrice":0.3954,"preClose":0.41,"latestTime":"09:20 EST","volume":1887,"amount":772.0417077,"timestamp":1765549213948},"postHourTrading":{"tag":"盘后","latestPrice":0.3877,"preClose":0.3894,"latestTime":"18:32 EST","volume":11964,"amount":4584.065,"timestamp":1765582367185},"volumeRatio":0.33111645391023564},"requestUrl":"/m/hq/s/AKTX/tweets","defaultTab":"tweets","newsList":[{"id":"2591830688","title":"European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2591830688","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591830688?lang=en_us&edition=fundamental","pubTime":"2025-12-13 00:17","pubTimestamp":1765556266,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending lower late Friday morning, falling 1% to 1,646.41 on the S&P Europe Select ADR Index, which is up 1.3% so far this week","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4020","LYG","BTI","CLLS","BK4532","BDRX","BK4082","LU0154236417.USD","DAVA","LU0109394709.USD","EDAP","LU0084288595.USD","BK4134","BK4588","BK4139","TEF","BK7104","BK4207","BK4115","BK4162","BK4521","DBVT","PUK","BK4142","IE00BMPRXN33.USD","LU0889565916.HKD","BK7062","EQNR","ASND","BTI.AU","IHG","LU2543165471.USD","LU0648005311.SGD","DAVA.AU","LU1093756325.SGD","LU1093756168.USD","LU0006061336.USD","AKTX","BK4117","AFG","NVO.AU","BK4107","AUTL","LU0320765992.SGD","BK4075","IE00BKVL7J92.USD","BK4547","IE00BZ1G4Q59.USD","NOK"],"gpt_icon":1},{"id":"2590510653","title":"European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2590510653","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590510653?lang=en_us&edition=fundamental","pubTime":"2025-12-12 00:10","pubTimestamp":1765469447,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were on the rise late Thursday morning, increasing 0.82% to 1,663.66 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion  and biopharmaceutical firm Cellectis , which rose 4.6% and 3.9%, respectively. They were followed by telecommunications company Nokia  and pharmaceutical firm Novo Nordisk , which advanced 3.6% and 2.6% respectively.The decliners from continental Europe were led by semiconductor company Sequans Communications  and medical device maker EDAP TMS , which fell 3.8% and 1.7% respectively. They were followed by oil and gas company Eni  and petroleum refiner Equinor , which were off 0.2% each.From the UK and Ireland, the gainers were led by cruise line operator Carnival  and biopharmaceutical company Akari Therapeutics , which increased 4% and 3.4% respectively. They were followed by communications company WPP  and alcoholic beverage company Diageo , whic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4142","IE00BKVL7J92.USD","SNN","WPP.AU","EVAX","BDRX","NCNA","BK4201","BK4559","IE00BMPRXN33.USD","E","BK4169","AFG","BK4139","DEO","BCYC","IE00BMPRXR70.SGD","BK4547","BK4532","DGE.UK","BK7104","LU1093756325.SGD","WPP","AKTX","BK4082","CUK","NOK","BK4107","LU1093756168.USD","SQNS","BK4020","EQNR","BK4117","BK4007","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4141","CLLS","BK4009","BK4585","NVO.AU","EDAP","BK4588","BK4599"],"gpt_icon":1},{"id":"2590539837","title":"European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2590539837","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590539837?lang=en_us&edition=fundamental","pubTime":"2025-12-11 00:08","pubTimestamp":1765382894,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were heading higher late Wednesday morning, rising 0.67% to 1,636.27 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies  and Cellectis , which climbed 14% and 6.8%, respectively. They were followed by pharmaceutical company Novo Nordisk  and brewing company Anheuser-Busch InBev , which advanced 3.8% and 1.8%, respectively.The decliners from continental Europe were led by biotech firm Evaxion  and semiconductor company Sequans Communications , which fell 3.8% and 2.1%, respectively. They were followed by internet advertising firm Criteo  and medical device maker EDAP TMS , which were down 1.9% each.From the UK and Ireland, the gainers were led by biopharmaceutical company Biodexa Pharmaceuticals  and lender HSBC , which rose 33% and 4.1%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics  and educational publish","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BUD","LU0052756011.USD","BK4141","BK4599","LU1093756325.SGD","BK7104","IE00BFMHRM44.USD","BK4585","EDAP","LU0128525689.USD","BK4207","IE00BZ1G4Q59.USD","SQNS","BK4007","AMRN","BK4204","EVAX","BK4111","AKTX","CLLS","BK4139","LU1267930227.SGD","BK4009","BK4082","BK4107","BDRX","BK4117","LU2236285917.USD","00005","CRTO","NCNA","BCYC","BK4532","BK4588","LU0154236417.USD","BK4521","DBVT","HSBC","BK4158","PSO","NVO","BK7119","TRIB","LU1093756168.USD","LU0310800965.SGD","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2590419283","title":"BRIEF-Akari Therapeutics Announces Preclinical Data On AKTX-101 For Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590419283","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590419283?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:41","pubTimestamp":1765287709,"startTime":"0","endTime":"0","summary":"BRIEF-Akari Therapeutics Announces Preclinical Data On AKTX-101 For Pancreatic CancerDec 9 (Reuters) - Akari Therapeutics PLC AKTX.O:AKARI THERAPEUTICS PLC - ANNOUNCES PRECLINICAL DATA ON AKTX-101 FOR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTX","BK4139","BK4007"],"gpt_icon":0},{"id":"2590834199","title":"Akari Therapeutics Plc - Announces Preclinical Data on Aktx-101 for Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590834199","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590834199?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:40","pubTimestamp":1765287650,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","AKTX"],"gpt_icon":0},{"id":"2590341995","title":"Akari Therapeutics Plc - Plans First-in-Human Trial for Aktx-101 in Late 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341995","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590341995?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:40","pubTimestamp":1765287650,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0N2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","AKTX"],"gpt_icon":0},{"id":"2590134125","title":"Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590134125","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590134125?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:40","pubTimestamp":1765287600,"startTime":"0","endTime":"0","summary":"Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest su","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202382/0/en/Akari-Therapeutics-Highlights-Preclinical-Data-Demonstrating-Therapeutic-Potential-of-Lead-Candidate-AKTX-101-for-Hard-to-Treat-K-Ras-Mutant-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTX"],"gpt_icon":0},{"id":"2590358352","title":"European Equities Traded in the US as ADRs Little Changed in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2590358352","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590358352?lang=en_us&edition=fundamental","pubTime":"2025-12-09 00:01","pubTimestamp":1765209714,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were little changed late Monday morning, easing less than 0.1% to 1,630.2 on the S&P Europe Select ADR Index.From continental Europe,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DEO","AMRN","BK4585","LU0300736062.USD","SNY","EVAX","BK4568","MTLS","BK7511","BK4588","BK4139","AKTX","LU1093756168.USD","IE00BZ1G4Q59.USD","TRIB","LU0124676726.USD","BK4082","BK4169","SLN","BK4532","BNTX","LU0689626769.HKD","LU1093756325.SGD","BK4599","DGE.UK","BK4168","BK4551","BDRX","IE00BFXG1179.USD","LU0154236417.USD","LU0300736492.USD","IE00BKVL7J92.USD","BK4548","UL","BK4559","BK4007","BK4535","BK4023","ULVR.UK","BK7104","BK7507","BK4183","AUTL","EDAP","BK4592","UN","DBVT","BHP","BK7095","BK4546"],"gpt_icon":1},{"id":"2588263887","title":"BRIEF-Akari Therapeutics Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2588263887","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588263887?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:04","pubTimestamp":1764857062,"startTime":"0","endTime":"0","summary":"BRIEF-Akari Therapeutics Provides Corporate Update Dec 4 (Reuters) - Akari Therapeutics PLC AKTX.O:AKARI THERAPEUTICS PROVIDES CORPORATE UPDATE AND HIGHLIGHTS ITS ADC PAYLOAD INNOVATION EXPECTED TO DR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA1Q1KYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","AKTX"],"gpt_icon":0},{"id":"2588688746","title":"Press Release: Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2588688746","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588688746?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:00","pubTimestamp":1764856800,"startTime":"0","endTime":"0","summary":"TAMPA, Fla. and LONDON, Dec. 04, 2025  -- Akari Therapeutics, Plc , an oncology biotechnology company developing novel payloads for antibody drug conjugates , today announced the publication of a new CEO Corner segment, now available on the Company's website. For this segment, Abizer Gaslightwala, CEO of Akari, provides a corporate update highlighting the Company's recent progress and key growth opportunities and timelines, what it means for the Company's path forward.This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","LENZ","ADC","AKTX","BK4539","BK4231","BK4139","BK4007"],"gpt_icon":0},{"id":"2588703489","title":"ADRs End Lower; Akari Therapeutics PLC Declines 17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588703489","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588703489?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:30","pubTimestamp":1764624600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed lower on Monday, as the S&P/BNY Mellon index of American depositary receipts declined 0.2% to 230.99.The European index fell 0.1% to 203.88. The Asian index dropped 0.2% to 307.56. The Latin American index declined 0.7% to 238.41, while the emerging-markets index dropped 0.2% to 515.15.Akari Therapeutics PLC, based in United Kingdom, posted the largest decline, tumbling 17% to 40 cents, followed by shares of Australia's Mobilicom Ltd., which tumbled 17% to $5.90. Shares of Italy-based Natuzzi S.p.A. tumbled 15% to $2.27.China's YXT.COM Group Holding Ltd. was the biggest leader during the session, soaring 29% to 83 cents, and China-based Yimutian Inc. surged 19% to $1.37. Belite Bio Inc., which is based in United States, rounded out the top three leaders on Monday, with shares surging 12% to $154.02.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTX","BK4139","BK4007"],"gpt_icon":0},{"id":"2586329382","title":"Akari Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2586329382","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586329382?lang=en_us&edition=fundamental","pubTime":"2025-11-27 06:01","pubTimestamp":1764194480,"startTime":"0","endTime":"0","summary":"Akari Therapeutics plc has received a notification from Nasdaq indicating that the company is not in compliance with the minimum bid price requirement, which mandates a closing bid price of at least $1.00 per share. The company has 180 calendar days, until May 25, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. If Akari does not meet this requirement by the deadline, it may be eligible for an additional 180-day compliance period if certain conditions are met. Failure to regain compliance could result in the delisting of its American Depositary Shares from the Nasdaq Capital Market, though the company would have the opportunity to appeal any delisting decision.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL3bT2Mh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKTX","BK4007"],"gpt_icon":0},{"id":"2586266977","title":"European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2586266977","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586266977?lang=en_us&edition=fundamental","pubTime":"2025-11-27 00:03","pubTimestamp":1764172980,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were surging higher late Wednesday morning, rising 1.25% to 1,614.11 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical companies Novo Nordisk  and Ascendis Pharma , which rose 3.5% and 1.8%, respectively. They were followed by biopharmaceutical company DBV Technologies  and lender Banco Santander , which were up 1.7% and 1.6%, respectively.The decliners from continental Europe were led by biopharmaceutical company Cellectis  and brewing company Anheuser-Busch InBev , which fell 4.6% and 1%, respectively. They were followed by biotech firm Evaxion  and pharmaceutical company Sanofi , which were off 0.9% each.From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics  and NuCana , which increased 5.5% and 3.7%, respectively. They were followed by lenders Barclays  and Lloyds Banking Group , which advanced 3.2% each.The decliners from the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4521","BK4559","BK7142","IE00BKVL7J92.USD","ASND","IE00BZ1G4Q59.USD","MREO","BK4139","BK7119","LYG","NVO.AU","AUTL","DEO","SNY","BUD","LU1093756168.USD","LU1093756325.SGD","BK4505","BCYC","AFG","BK4107","IE00BFXG1179.USD","BK4585","BK4158","LU0889565916.HKD","SAN","LU0320765992.SGD","EVAX","SAN.AU","BK4588","BK7104","BUD.AU","LU0109394709.USD","BK4117","BK4169","LU0154236417.USD","NVO","BK4007","BK4599","CLLS","DBVT","BK4207","AKTX","NCNA","BK4532","DGE.UK","BCS"],"gpt_icon":1},{"id":"2586562496","title":"European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2586562496","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586562496?lang=en_us&edition=fundamental","pubTime":"2025-11-25 00:14","pubTimestamp":1764000859,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts opened the week little changed late Monday morning, edging 0.1% higher to 1,572.55 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and internet browser company Opera , which advanced 10% and 2.4%, respectively. They were followed by medical device maker EDAP TMS  and telecommunications company Nokia , which increased 1.7% and 1.5%, respectively.The decliners from continental Europe were led by pharmaceutical company Novo Nordisk  and internet advertising firm Criteo , which fell 7.8% and 1.4%, respectively. They were followed by oil and gas company Eni , which was down 1%.From the UK and Ireland, the gainers were led by biopharmaceutical companies Mereo BioPharma Group  and Bicycle Therapeutics , which rose 3.6% each. They were followed by biotech firm Trinity Biotech  and biopharmaceutical company NuCana , which were up 3.2% and 1.7%, respectively","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4201","WPP","EDAP","BK4117","NVO","BK4107","BK4505","BK4585","BK4007","CLLS","BDRX","BK4599","LU1093756325.SGD","BK7104","LU0154236417.USD","NCNA","BK4009","CRTO","IE00BMPRXR70.SGD","IE00BFMHRM44.USD","AFG","NVO.AU","EVAX","BK4547","OPRA","BK4208","AKTX","BK4020","BK4023","BK4532","IE00BKVL7J92.USD","BCYC","MREO","E","TRIB","BK4139","LU1093756168.USD","IE00BMPRXN33.USD","NOK","BK4588","NGG","WPP.AU","BK4082","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2584475189","title":"Analysts’ Top Healthcare Picks: Qiagen (QGEN), Akari Therapeutics (AKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584475189","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584475189?lang=en_us&edition=fundamental","pubTime":"2025-11-20 16:10","pubTimestamp":1763626213,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Qiagen (QGEN – Research Report) and Akari Therapeuti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-qiagen-qgen-akari-therapeutics-aktx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-qiagen-qgen-akari-therapeutics-aktx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2433249047.HKD","HCSG","BK4585","BK4139","XBI","LABU","XLV","QGEN","LU0029874061.USD","BK4121","BK4007","BK4137","BK4581","LU2125909247.SGD","AKTX","LU0128526141.USD","BK4588","LU1923622614.USD","LU2125909593.SGD"],"gpt_icon":0},{"id":"2584397958","title":"BRIEF-Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag As Interim Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584397958","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584397958?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:37","pubTimestamp":1763473031,"startTime":"0","endTime":"0","summary":"BRIEF-Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag As Interim Chief Financial OfficerAkari Therapeutics PLC AKTX.O:AKARI THERAPEUTICS APPOINTS BIOTECH FINANCE LEADER, KAMEEL D. FARAG AS INTERIM CHIEF FINANCIAL OFFICERSource text: ID:nGNX14XkQ4Further company coverage: AKTX.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUA98WFPX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AKTX","BK4139"],"gpt_icon":0},{"id":"2584300609","title":"Press Release: Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584300609","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584300609?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:35","pubTimestamp":1763472900,"startTime":"0","endTime":"0","summary":"TAMPA and LONDON, Nov. 18, 2025  -- Akari Therapeutics, Plc , an oncology biotechnology company developing novel payloads for antibody drug conjugates , today announced the appointment of Kameel D. Farag as its Interim Chief Financial Officer who joined Akari last month. Mr. Farag is a proven biotech and global finance executive with a track record spanning over two decades of scaling innovative biotech companies through transformational growth.\"We are thrilled to welcome Kameel to Akari, who has hit the ground running, at a pivotal time in our company's growth,\" said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. \"His deep experience across corporate finance, M&A, and operational build-outs will be instrumental as we accelerate development of our novel ADC platform and advance our lead asset toward the clinic.\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","AKTX","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2584627021","title":"European Equities Traded in the US as American Depositary Receipts Slightly Lower in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2584627021","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584627021?lang=en_us&edition=fundamental","pubTime":"2025-11-18 00:19","pubTimestamp":1763396365,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were slightly lower late Monday morning, edging 0.1% lower to 1,610.86 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and pharmaceutical company Ascendis Pharma , which climbed 7.5% and 7.2%, respectively. They were followed by biopharmaceutical companies DBV Technologies  and Genfit , which advanced 5.4% and 3.5%, respectively.The decliners from continental Europe were led by software firm SAP  and lender Banco Santander , which fell 1.9% each. They were followed by brewing company Anheuser-Busch InBev  and health technology company Philips , which were down 1.6% and 1.4%, respectively.From the UK and Ireland, the gainers were led by communications company WPP  and biopharmaceutical company Mereo BioPharma Group , which rose 11% and 2.5%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics  and pharmaceutical compan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SAN.AU","BK4585","BK4139","GSK","BK4521","BK4158","LU0109394709.USD","AFG","BK4107","AKTX","GNFTY","BK4009","BK7142","PHG","BK4532","DBVT","ASND","BK4588","SAN","SAP","GNFT","BK4117","MREO","NCNA","BK4207","GSK.UK","BDRX","WPP.AU","LU0320765992.SGD","BCYC","BUD","BK4528","BK4007","BK4082","LU0889565916.HKD","WPP","BK7119","BK4023","LU1829250122.USD","CLLS","BK4505","BK4613","TRIB","BUD.AU"],"gpt_icon":0},{"id":"2582803070","title":"European Equities Traded in the US as American Depositary Receipts Start Week Trending Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2582803070","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582803070?lang=en_us&edition=fundamental","pubTime":"2025-11-11 00:05","pubTimestamp":1762790700,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts opened the week higher late Monday morning, rising 0.77% to 1,603.65 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies Cellectis  and Genfit , which climbed 12.2% and 7.2% respectively. They were followed by 3D printer company Materialise  and lender Banco Bilbao Vizcaya Argentaria , which advanced 4.8% and 2.4% respectively.The decliners from continental Europe were led by petroleum refiner Equinor  and telecommunications operator Telefonica , which fell 2.2% and 1.4% respectively. They were followed by consumer goods giant Unilever  and telecommunications company Ericsson , which were down 1% and 0.8% respectively.From the UK and Ireland, the gainers were led by alcoholic beverage company Diageo  and biotech firm Autolus Therapeutics , which rose 4.9% and 2.2% respectively. They were followed by pharmaceutical company AstraZeneca  and biopharmaceutical comp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ERIC","AMRN","AKTX","BK4591","SLN","UN","BK4201","LU0084288595.USD","BK4007","LU0109394709.USD","LU2236285917.USD","LU2456880835.USD","UL","BK4559","BK4554","BK4207","BK4183","BBVA","BDRX","AFG","EQNR","BK4107","DAVA","GNFT","BK4117","BK4169","LU0689626769.HKD","BK4023","BK4588","LU0124676726.USD","LU0648005311.SGD","BK4515","LU0320765992.SGD","DGE.UK","DEO","TEF","BK4020","BK4592","BK4546","CLLS","AUTL","DAVA.AU","ULVR.UK","LU0889565916.HKD","LU2462157665.USD","BK4568","AZN","BK4134","MTLS","LU1829250122.USD"],"gpt_icon":0},{"id":"2582874803","title":"Akari Therapeutics Unveils Promising Preclinical Data for Novel Splicing-Targeted ADC Payload PH1","url":"https://stock-news.laohu8.com/highlight/detail?id=2582874803","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582874803?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:35","pubTimestamp":1762781759,"startTime":"0","endTime":"0","summary":"Akari Therapeutics plc has announced the initiation of IND-enabling studies for its lead antibody-drug conjugate  candidate, AKTX-101, which targets the Trop2 receptor on cancer cells using a proprietary linker and a novel PH1 payload. The PH1 payload is designed to disrupt the spliceosome and has demonstrated a unique preclinical efficacy and safety profile. Results from preclinical studies, including data showing that a Trastuzumab PH1 combination with anti-PD1 produced a statistically significantly higher rate of complete responses compared to Kadcyla + anti-PD1 , were recently presented at the 40th Annual SITC Meeting. Additional immune mechanism-of-action data for the PH1 payload were also presented at this conference. Akari plans to advance AKTX-101 into clinical trials in the near future and will host a webcast to discuss the presented data on November 18, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL2x5xyp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","AKTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akaritx.com","stockEarnings":[{"period":"1week","weight":0.1487},{"period":"1month","weight":-0.2827},{"period":"3month","weight":-0.5065},{"period":"6month","weight":-0.6728},{"period":"1year","weight":-0.5901},{"period":"ytd","weight":-0.6808}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.025064},{"month":2,"riseRate":0.181818,"avgChangeRate":-0.180423},{"month":3,"riseRate":0.416667,"avgChangeRate":0.093515},{"month":4,"riseRate":0.416667,"avgChangeRate":0.053226},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.154522},{"month":6,"riseRate":0.5,"avgChangeRate":0.049768},{"month":7,"riseRate":0.333333,"avgChangeRate":0.024132},{"month":8,"riseRate":0.5,"avgChangeRate":0.23135},{"month":9,"riseRate":0.5,"avgChangeRate":0.047326},{"month":10,"riseRate":0.25,"avgChangeRate":-0.130903},{"month":11,"riseRate":0.416667,"avgChangeRate":-0.07207},{"month":12,"riseRate":0.25,"avgChangeRate":-0.079567}],"exchange":"NASDAQ","name":"Akari Therapeutics PLC","nameEN":"Akari Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Akari Therapeutics PLC(AKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Akari Therapeutics PLC(AKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Akari Therapeutics PLC,AKTX,Akari Therapeutics PLC股票,Akari Therapeutics PLC股票老虎,Akari Therapeutics PLC股票老虎国际,Akari Therapeutics PLC行情,Akari Therapeutics PLC股票行情,Akari Therapeutics PLC股价,Akari Therapeutics PLC股市,Akari Therapeutics PLC股票价格,Akari Therapeutics PLC股票交易,Akari Therapeutics PLC股票购买,Akari Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Akari Therapeutics PLC(AKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Akari Therapeutics PLC(AKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction